This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
by Kinjel Shah
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Company News for Apr 2, 2025
by Zacks Equity Research
Companies In The News Are: PVH, PRGS,RBLX, GOOGL, HIMS, LLY.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.
Is the Future Bleak for SAVA Stock Following Another Setback?
by Zacks Equity Research
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Eli Lilly (LLY) closed at $852.35 in the latest trading session, marking a -1.45% move from the prior day.
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
by Zacks Equity Research
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
by Nalak Das
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
J&J to Invest $55B in United States to Boost Manufacturing, R&D
by Zacks Equity Research
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
by Zacks Equity Research
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Eli Lilly (LLY) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $822.51, signifying a -0.27% move from its prior day's close.
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
by Zacks Equity Research
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
NVO vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVO vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
by Zacks Equity Research
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?